Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.

Trial Profile

Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Trabectedin (Primary)
  • Indications Ovarian cancer; Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms TRAMUNE
  • Most Recent Events

    • 12 May 2017 Planned End Date changed from 15 May 2021 to 5 May 2021.
    • 12 May 2017 Planned primary completion date changed from 15 May 2020 to 5 May 2020.
    • 12 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top